Agenus Reports 72% Pathologic Complete Response Rate with BOT+BAL in Phase 2 NEOASIS Trial at ESMO 2026

Agenus presented Phase II NEOASIS study results at ESMO 2026, showing 83% pathological response rate in dMMR colorectal cancer patients treated with neoadjuvant botensilimab plus balstilimab. 72% achieved complete response. Safety profile included Grade 1-2 immune-related adverse events in 72% of patients, with one Grade 3 colitis case. The study met its primary endpoint, supporting further evaluation.

Agenus reported 72% pathologic complete response in 18 dMMR colon cancer patients treated with botensilimab and balstilimab in a Phase 2 study. 83% achieved major pathologic response. All patients were alive at 15-month median follow-up, with 16 showing no recurrence. The study was presented at the ESMO Congress.

Agenus (AGEN) reported that 72% of patients in a phase 2 trial for locally advanced colon cancer had no detectable cancer at surgery after a six-week immunotherapy course, according to results presented at the European Society for Medical Oncology Congress.

Agenus Inc. (AGEN) reported Phase 2 NEOASIS study results showing 83% of 18 patients with locally advanced dMMR colon cancer achieved a major pathologic response, with 72% having no cancer remaining at surgery after a 6-week course of botensilimab and balstilimab. Side effects were mostly mild. The company is exploring this approach in rectal cancer and MSS colon cancer.

Agenus Inc. reported Phase 2 NEOASIS study results, showing 83% MPR and 72% pCR in 18 dMMR colon cancer patients treated with botensilimab plus balstilimab. The company aims to expand use across tumors, pending further studies and regulatory discussions.

Agenus' botensilimab and balstilimab combination therapy showed 83% of patients with locally advanced dMMR colon cancer had little or no cancer remaining at surgery. The NEOASIS study met its primary endpoint, with mild side effects reported. Agenus is exploring organ preservation in rectal cancer and advancing the approach in MSS colon cancer. The company aims to reduce treatment duration and chemotherapy use.